Skip to content
value.today

Eledon Pharmaceuticals, Inc.

ELDN
$257 Mmarket cap on Oct 30, 2026+446.3% since Jan 2024
Compare
World rank
#15,375
Revenue
—
For year ending December-2025
Net income
$-46 M
SEC filing
Employees
33
As of March 13, 2026
SEC filing

Eledon Pharmaceuticals, Inc. in brief

Eledon Pharmaceuticals, Inc. is a listed company in the Biotechnology industry, based in Irvine, California, USA. Its market value was $257 M on 30 October 2026, which makes it the 15,375th largest listed company in the world and the 3,003rd largest in the USA on this site. It employs about 33 people and David-Alexandre C. Gros is its chief executive. Its shares trade under the symbol ELDN (Nasdaq).

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

About Eledon Pharmaceuticals, Inc.

Eledon is a clinical stage biotechnology company using our immunology expertise in targeting the CD40 Ligand pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis. Our lead compound in development is tegoprubart, an IgG1, anti-CD40L antibody with high affinity for the CD40L, a well-validated biological target that we believe has broad therapeutic potential. We believe the central role of CD40L signaling in both adaptive and innate immune cell activation and function positions it as an attractive target for non-lymphocyte depleting, immunomodulatory therapeutic intervention.

From the company's annual report filed with the US SEC: read the report

Eledon Pharmaceuticals, Inc. timeline

4 events, 2007–2020
  1. 2007
  2. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  3. 2014
  4. 🔔
    Initial public offering as Tokai Pharmaceuticals Inc
    Final prospectus filed with the SEC on 18 September 2014; shares registered for exchange trading on 12 September 2014.
  5. 2017
  6. ✎
    Renamed Novus Therapeutics, Inc.
    Formerly Tokai Pharmaceuticals Inc.
  7. 2020
  8. ✎
    Renamed Eledon Pharmaceuticals, Inc.
    Formerly Novus Therapeutics, Inc..

Events of Eledon Pharmaceuticals, Inc. from SEC EDGAR. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

$0 M$74 M$147 M$221 M$295 M2023202420252026

World rank over time

▲ up 11,618 places since 2022
2022-12-25: #27039#27,03920222023-07-30: #27837#27,83720232024-01-05: #25183#25,18320242026-03-08: #9246#9,24620262026-08-01: #14509#14,50920262026-10-14: #16383#16,38320262026-10-30: #15421#15,4212026

Rank in USA: #5,023 (Dec 2022) · #5,026 (Jul 2023) · #4,092 (Jan 2024) · #1,778 (Mar 2026) · #2,929 (Aug 2026) · #3,145 (Oct 2026) · #3,007 (Oct 2026)

Key ratios

market cap and latest results
P/E ratio
n/m (loss)
Price / sales
—
Price / book
3.2×
Free cash flow yield
-1.9%
Net margin
—
Operating margin
—
Return on equity
-56.3%
Liabilities / assets
19.1%
Profit per employee
$-1.4 M

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Dec 2018: revenue —, net income $-14M—FY18Fiscal year ending Dec 2019: revenue —, net income $-16M—FY19Fiscal year ending Dec 2020: revenue —, net income $-23M—FY20Fiscal year ending Dec 2021: revenue —, net income $-35M—FY21Fiscal year ending Dec 2022: revenue —, net income $-88M—FY22Fiscal year ending Dec 2023: revenue —, net income $-117M—FY23Fiscal year ending Dec 2024: revenue —, net income $-36M—FY24Fiscal year ending Dec 2025: revenue —, net income $-46M—FY25
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Dec 2025———$-46M—
Dec 2024———$-36M—
Dec 2023——$-43M$-117M—
Dec 2022——$-88M$-88M—
Dec 2021——$-37M$-35M—
Dec 2020——$-18M$-23M—
Dec 2019——$-16M$-16M—
Dec 2018——$-14M$-14M—

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Dec 2025$-62M——$-0.52—
Dec 2024$-47M——$-0.66—
Dec 2023$-40M——$-4.73—
Dec 2022$-28M——$-6.16—
Dec 2021$-29M——$-2.33—
Dec 2020$-15M——$-15.72—
Dec 2019$-14M——$-24.42—
Dec 2018$-12M——$-1.56—

Quarterly results

USD · three months to · source: SEC filings
RevenueNet income
Three months to Dec 2024 (from the annual report): revenue —, net income $-45M—Dec ’24Three months to Mar 2025: revenue —, net income $-7M—Mar ’25Three months to Jun 2025: revenue —, net income $-11M—Jun ’25Three months to Sep 2025: revenue —, net income $-17M—Sep ’25Three months to Dec 2025 (from the annual report): revenue —, net income $-10M—Dec ’25Three months to Mar 2026: revenue —, net income $-39M—Mar ’26Three months to Jun 2026: revenue —, net income $-32M—Jun ’26Three months to Sep 2026: revenue —, net income $-4M—Sep ’26

Latest quarter to Sep 2026: revenue —, net income $-4M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.

SEC filings

Official filings of Eledon Pharmaceuticals, Inc. with the US Securities and Exchange Commission.

Annual results

Revenue
—
Operating income
—
Net income
$-46 M

For year ending December-2025 · source: SEC filing

Balance sheet

Total assets
$169 M
Total liabilities
$32 M
Total equity
$81 M

As of December-2025

Top 100 institutional investors in Eledon Pharmaceuticals, Inc.#

As of Sep 30, 2026
155 institutions held 45.5 M shares (about 53.9% of the shares outstanding) on Sep 30, 2026. The ten largest hold 36.5%. Source: SEC Form 13F filings, filed through Nov 17, 2026. Change is since the previous quarter.This quarter is still being filed: about 99% of the institutions that reported last quarter have filed so far. Institutions that have not filed yet are missing from the list, not sellers; the list is brought up to date every day.
The 25 largest institutional investors in Eledon Pharmaceuticals, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
1BlackRock, Inc.6,641,297+1,517,455 (+29.62%)7.86%$17 MNov 13, 2026
2BVF Inc/il6,293,2820 (0.00%)7.45%$16 MNov 16, 2026
3Defilade Capital Management, L.P.3,525,3380 (0.00%)4.17%$9 MNov 16, 2026
4Vanguard Capital Management LLC3,417,2230 (0.00%)4.05%$9 MNov 13, 2026
5Goldman Sachs Group Inc2,561,285+50,977 (+2.03%)3.03%$6 MNov 16, 2026
6Geode Capital Management, LLC1,980,977+24,376 (+1.25%)2.35%$5 MNov 6, 2026
7Ensign Peak Advisors, Inc1,756,223-345,001 (-16.42%)2.08%$4 MNov 12, 2026
8Catalio Capital Management, LP1,637,114-57,957 (-3.42%)1.94%$4 MNov 16, 2026
9State Street Corp1,614,898-7,071 (-0.44%)1.91%$4 MNov 12, 2026
10Sphera Funds Management LTD.1,392,187+201,000 (+16.87%)1.65%$4 MNov 16, 2026
11Zimmer Partners, LP1,200,000-396,599 (-24.84%)1.42%$3 MNov 16, 2026
12AWM Investment Company, Inc.1,100,0000 (0.00%)1.30%$3 MNov 13, 2026
13Millennium Management LLC789,861-189,851 (-19.38%)0.94%$2 MNov 16, 2026
14ADAR1 Capital Management, LLC652,812+5,000 (+0.77%)0.77%$2 MNov 16, 2026
1522NW, LP636,3640 (0.00%)0.75%$2 MNov 13, 2026
16Northern Trust Corp630,758+14,359 (+2.33%)0.75%$2 MNov 16, 2026
17Vanguard Fiduciary Trust Co575,672+46,709 (+8.83%)0.68%$1 MNov 13, 2026
18Blue Owl Capital Holdings LP566,5090 (0.00%)0.67%$1 MNov 13, 2026
19Renaissance Technologies LLC556,900+356,000 (+177.20%)0.66%$1 MNov 12, 2026
20Vanguard Portfolio Management LLC542,676+9,311 (+1.75%)0.64%$1 MNov 13, 2026
21UBS Group AG532,686-515,559 (-49.18%)0.63%$1 MNov 10, 2026
22CM Management, LLC525,000-50,000 (-8.70%)0.62%$1 MNov 12, 2026
23Dimensional Fund Advisors LP511,559-27,179 (-5.04%)0.61%$1 MNov 4, 2026
24Jacobs Levy Equity Management, Inc484,760+374,919 (+341.33%)0.57%$1 MNov 16, 2026
25BIT Capital GmbH427,000+161,000 (+60.53%)0.51%$1 MNov 13, 2026
Show all 100: investors 26 to 100
Institutional investors 26 to 100 in Eledon Pharmaceuticals, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
26Brevan Howard Capital Management LP381,447+76,740 (+25.18%)0.45%$1 MNov 16, 2026
27Triumph Capital Management316,509+13,066 (+4.31%)0.37%$1 MOct 14, 2026
28Bank Of America Corp /de/307,463-575,634 (-65.18%)0.36%$1 MNov 16, 2026
29Qube Research & Technologies Ltd271,051New0.32%$1 MNov 13, 2026
30Morgan Stanley250,903-234,189 (-48.28%)0.30%$1 MNov 13, 2026
31Charles Schwab Investment Management Inc247,406+2 (0.00%)0.29%$1 MNov 16, 2026
32Nuveen, LLC224,041+14,944 (+7.15%)0.27%$1 MNov 10, 2026
33Bank of New York Mellon Corp158,917-8,010 (-4.80%)0.19%$0 MNov 5, 2026
34Susquehanna International Group, LLP144,158-108,074 (-42.85%)0.17%$0 MNov 16, 2026
35Susquehanna Portfolio Strategies, LLC140,675+68,756 (+95.60%)0.17%$0 MNov 16, 2026
36Russell Investments Group, Ltd.127,933+87,010 (+212.62%)0.15%$0 MNov 6, 2026
37LPL Financial LLC122,055+10,360 (+9.28%)0.14%$0 MNov 6, 2026
38FMR LLC95,110+88,875 (+1425.42%)0.11%$0 MNov 10, 2026
39Daytona Street Capital LLC91,666+10,500 (+12.94%)0.11%$0 MOct 15, 2026
40Rhumbline Advisers87,988-621 (-0.70%)0.10%$0 MNov 10, 2026
41Prodigy Asset Management LLC86,7030 (0.00%)0.10%$0 MOct 28, 2026
42AQR Capital Management LLC76,215-504,813 (-86.88%)0.09%$0 MNov 16, 2026
43Raymond James Financial Inc76,194+40,781 (+115.16%)0.09%$0 MNov 12, 2026
44Farmers & Merchants Investments Inc74,123+67,802 (+1072.65%)0.09%$0 MOct 22, 2026
45Rockefeller Capital Management L.P.72,6660 (0.00%)0.09%$0 MNov 13, 2026
46Public Employees Retirement System Of Ohio68,065New0.08%$0 MNov 16, 2026
47Deutsche Bank AG\67,170-9,473 (-12.36%)0.08%$0 MNov 6, 2026
48Price T Rowe Associates Inc /MD/63,9840 (0.00%)0.08%$0 MNov 16, 2026
49Invesco Ltd.58,237-1,060 (-1.79%)0.07%$0 MNov 12, 2026
50PW Nova Financial Services LLC58,0410 (0.00%)0.07%$0 MOct 15, 2026
51Point72 Asset Management, L.P.53,247New0.06%$0 MNov 16, 2026
52Ingalls & Snyder LLC51,8490 (0.00%)0.06%$0 MNov 12, 2026
53Simplex Trading, LLC46,866-41,731 (-47.10%)0.06%$0 MNov 4, 2026
54Spark Investment Management LLC40,800New0.05%$0 MNov 13, 2026
55Jump Financial, LLC40,708+19,427 (+91.29%)0.05%$0 MNov 13, 2026
56Citigroup Inc39,013+2,935 (+8.14%)0.05%$0 MNov 4, 2026
57Jpmorgan Chase & Co38,554+6,243 (+19.32%)0.05%$0 MNov 12, 2026
58MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.37,366+1,893 (+5.34%)0.04%$0 MNov 16, 2026
59Barclays PLC36,445+24,556 (+206.54%)0.04%$0 MNov 6, 2026
60Vanguard Global Advisers, LLC36,083+11,147 (+44.70%)0.04%$0 MNov 13, 2026
61Wells Fargo & Company/mn33,138-41,806 (-55.78%)0.04%$0 MNov 16, 2026
62Alliancebernstein L.P.32,4000 (0.00%)0.04%$0 MNov 16, 2026
63Citadel Advisors LLC32,201-183,772 (-85.09%)0.04%$0 MNov 16, 2026
64Jones Financial Companies Lllp30,833+10,881 (+54.54%)0.04%$0 MNov 13, 2026
65Marco Investment Management LLC30,3440 (0.00%)0.04%$0 MNov 9, 2026
66Cetera Investment Advisers30,267+1,400 (+4.85%)0.04%$0 MNov 13, 2026
67Retirement Planning Group, LLC30,0010 (0.00%)0.04%$0 MOct 19, 2026
68Howard Financial Services, LTD.30,000-30,000 (-50.00%)0.04%$0 MOct 15, 2026
69MetLife Investment Management, LLC29,100-11,818 (-28.88%)0.03%$0 MNov 16, 2026
70SEI Investments Co27,1210 (0.00%)0.03%$0 MNov 10, 2026
71Police & Firemen's Retirement System of New Jersey23,5080 (0.00%)0.03%$0 MNov 9, 2026
72Manufacturers Life Insurance Company, The22,537+1,086 (+5.06%)0.03%$0 MNov 13, 2026
73BNP Paribas Financial Markets19,903+8,710 (+77.82%)0.02%$0 MNov 12, 2026
74Commonwealth Equity Services, LLC19,754+3,198 (+19.32%)0.02%$0 MNov 2, 2026
75Mariner, LLC17,615-32,426 (-64.80%)0.02%$0 MNov 12, 2026
76China Universal Asset Management Co., Ltd.16,900+900 (+5.62%)0.02%$0 MOct 28, 2026
77Cambridge Investment Research Advisors, Inc.16,830-103,060 (-85.96%)0.02%$0 MNov 2, 2026
78Private Advisor Group, LLC16,390-5,370 (-24.68%)0.02%$0 MNov 10, 2026
79Baker Ellis Asset Management LLC16,0000 (0.00%)0.02%$0 MOct 14, 2026
80Voya Investment Management LLC15,9060 (0.00%)0.02%$0 MNov 10, 2026
81Claro Advisors Inc.15,897New0.02%$0 MNov 2, 2026
82Ancora Advisors LLC15,000New0.02%$0 MNov 17, 2026
83Blair William & Co/il14,500-443 (-2.96%)0.02%$0 MNov 10, 2026
84Neuberger Berman Group LLC14,360+1,114 (+8.41%)0.02%$0 MNov 13, 2026
85Independent Advisor Alliance14,3000 (0.00%)0.02%$0 MNov 10, 2026
86Revolve Wealth Partners, LLC14,1430 (0.00%)0.02%$0 MOct 23, 2026
87Mercer Global Advisors Inc /adv13,987-19,512 (-58.25%)0.02%$0 MNov 16, 2026
88XTX Topco Ltd13,814-24,493 (-63.94%)0.02%$0 MNov 16, 2026
89Signaturefd, LLC12,9350 (0.00%)0.02%$0 MOct 23, 2026
90Two Sigma Investments, LP12,638-20,307 (-61.64%)0.01%$0 MNov 16, 2026
91Two Sigma Securities, LLC12,477New0.01%$0 MNov 16, 2026
92Waverly Advisors, LLC12,256-1,596 (-11.52%)0.01%$0 MNov 16, 2026
93Corient Private Wealth LP12,057-6,071 (-33.49%)0.01%$0 MNov 16, 2026
94HUB Investment Partners, LLC11,746New0.01%$0 MNov 3, 2026
95Prudential Financial Inc11,5200 (0.00%)0.01%$0 MNov 16, 2026
96Summit Financial, LLC11,5000 (0.00%)0.01%$0 MNov 12, 2026
97StoneX Group Inc.11,350New0.01%$0 MNov 3, 2026
98Apollon Financial, LLC11,258New0.01%$0 MOct 23, 2026
99Creative Planning11,104-12,355 (-52.67%)0.01%$0 MNov 2, 2026
100Susquehanna Fundamental Investments, LLC10,9750 (0.00%)0.01%$0 MNov 16, 2026

All 155 institutional investors, with who bought and sold →

Mutual funds holding Eledon Pharmaceuticals, Inc.#

91 funds hold shares worth $43 M (about 13.3% of the company). Since their previous reports 66 added shares and 15 sold, buying $7 M net.
Mutual funds holding Eledon Pharmaceuticals, Inc.
FundSharesValueOf the companyOf the fundChange in sharesReport
🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc.2.48 M$10 M2.9%<0.01%+5.4%Jun 30, 2026
🇺🇸 iShares Russell 2000 ETFBlackRock Fund Advisors2.04 M$8 M2.4%<0.01%+14%Jun 30, 2026
🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc.854,634$3 M1.0%<0.01%−0.4%Jun 30, 2026
🇺🇸 iShares Russell 2000 Growth ETFBlackRock Fund Advisors723,407$3 M0.86%0.02%+1730%Jun 30, 2026
🇺🇸 Fidelity Small Cap Index FundFidelity Management & Research Company LLC839,205$3 M0.99%<0.01%+13%Jul 31, 2026
🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC389,371$1 M0.46%<0.01%+3.4%May 31, 2026
🇺🇸 Vanguard Russell 2000 Index FundThe Vanguard Group, Inc.383,983$1 M0.45%<0.01%+39%May 31, 2026
🇺🇸 Goldman Sachs Small Cap Equity Insights FundGoldman Sachs Asset Management, L.P.311,993$1 M0.37%0.10%+138%Jul 31, 2026
🇺🇸 iShares Micro-Cap ETFBlackRock Fund Advisors255,233$1 M0.30%0.07%+36%Jun 30, 2026
🇺🇸 Goldman Sachs Small Cap Value Insights FundGoldman Sachs Asset Management, L.P.286,012$1 M0.34%0.07%−13%Jul 31, 2026
🇺🇸 Dimensional U.S. Small Cap ETFDimensional Fund Advisors LP196,897$1 M0.23%<0.01%+19%Jul 31, 2026
🇺🇸 Schwab Small-Cap Index FundCharles Schwab Investment Management, Inc.187,417$1 M0.22%<0.01%+14%Jul 31, 2026
🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC141,649$1 M0.17%<0.01%+15%May 31, 2026
🇺🇸 Master Small Cap Index SeriesBlackRock Advisors, LLC134,953$1 M0.16%<0.01%no changeJun 30, 2026
🇺🇸 Goldman Sachs Small Cap Growth Insights FundGoldman Sachs Asset Management, L.P.129,548$0 M0.15%0.13%+151%Jul 31, 2026
🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC111,465$0 M0.13%<0.01%+12%May 31, 2026
🇺🇸 Nuveen Small Cap Blend Index FundTeachers Advisors, LLC102,669$0 M0.12%<0.01%+35%Jul 31, 2026
🇺🇸 EQ/2000 Managed Volatility PortfolioEquitable Investment Management Group, LLC85,200$0 M0.10%<0.01%−0.0%Jun 30, 2026
🇺🇸 Goldman Sachs Variable Insurance Trust Small Cap Equity Insights FundGoldman Sachs Asset Management, L.P.81,409$0 M0.10%0.14%+328%Jun 30, 2026
🇺🇸 NVIT GS Small Cap Equity Insights FundNATIONWIDE FUND ADVISORS81,103$0 M0.10%0.15%+954%Jun 30, 2026
🇺🇸 U.S. Micro Cap PortfolioDimensional Fund Advisors LP92,156$0 M0.11%<0.01%+274%Jul 31, 2026
🇺🇸 Fidelity Small Cap Growth Index FundFidelity Management & Research Company LLC72,107$0 M0.09%0.02%+1897%Jun 30, 2026
🇺🇸 Nuveen Equity Index FundTeachers Advisors, LLC79,307$0 M0.09%<0.01%newJul 31, 2026
🇺🇸 LVIP State Street Small-Cap Index FundLincoln Financial Investments Corporation56,600$0 M0.07%<0.01%+49%Jun 30, 2026
🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC57,445$0 M0.07%<0.01%+65%May 31, 2026
🇺🇸 Vanguard Russell 2000 Value Index FundThe Vanguard Group, Inc.53,969$0 M0.06%0.02%+35%May 31, 2026
🇺🇸 Schwab Total Stock Market Index FundCharles Schwab Investment Management, Inc.59,987$0 M0.07%<0.01%no changeJul 31, 2026
🇺🇸 U.S. Small Cap PortfolioDimensional Fund Advisors LP54,836$0 M0.06%<0.01%+867%Jul 31, 2026
🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc.43,564$0 M0.05%<0.01%no changeJun 30, 2026
🇺🇸 Small Cap Index FundNorthern Trust Investments, Inc.39,749$0 M0.05%<0.01%+21%Jun 30, 2026
🇺🇸 Dimensional U.S. Core Equity 2 ETFDimensional Fund Advisors LP45,699$0 M0.05%<0.01%+162%Jul 31, 2026
🇺🇸 Avantis U.S. Small Cap Equity ETFAmerican Century ETF Trust39,630$0 M0.05%<0.01%+734%May 31, 2026
🇺🇸 Vanguard Institutional Total Stock Market Index FundThe Vanguard Group, Inc.35,863$0 M0.04%<0.01%no changeJun 30, 2026
🇺🇸 Fidelity ZERO Total Market Index FundFidelity Management & Research Company LLC38,593$0 M0.05%<0.01%no changeJul 31, 2026
🇺🇸 Bridge Builder Small/Mid Cap Value FundOLIVE STREET INVESTMENT ADVISERS LLC33,007$0 M0.04%<0.01%no changeJun 30, 2026
🇺🇸 Global X Russell 2000 ETFGlobal X Management Company LLC36,789$0 M0.04%<0.01%+14%Jul 31, 2026
🇺🇸 Goldman Sachs Absolute Return Tracker FundGoldman Sachs Asset Management, L.P.30,676$0 M0.04%<0.01%−31%Jun 30, 2026
🇺🇸 Small Cap Index FundThe Variable Annuity Life Insurance Company30,905$0 M0.04%<0.01%+56%May 31, 2026
🇺🇸 PACE Small/Medium Co Growth Equity InvestmentsUBS Asset Management (Americas) LLC33,800$0 M0.04%0.04%newJul 31, 2026
🇺🇸 Diversified Equity Alpha Master PortfolioBlackRock Fund Advisors25,778$0 M0.03%<0.01%newJun 30, 2026
🇺🇸 State Street Small/mid Cap Equity Index PortfolioSSGA Funds Management, Inc.25,500$0 M0.03%<0.01%no changeJun 30, 2026
🇺🇸 MetLife Russell 2000 Index PortfolioBrighthouse Investment Advisers, LLC23,250$0 M0.03%<0.01%−4.9%Jun 30, 2026
🇺🇸 Fidelity ZERO Extended Market Index FundFidelity Management & Research Company LLC26,679$0 M0.03%<0.01%+3.0%Jul 31, 2026
🇺🇸 Small-Cap Index PortfolioPacific Life Fund Advisors LLC22,071$0 M0.03%<0.01%+46%Jun 30, 2026
🇺🇸 AVIP BlackRock Advantage Small Cap Growth PortfolioCONSTELLATION INVESTMENTS INC20,297$0 M0.02%0.06%newJun 30, 2026
🇺🇸 ATM Small Cap Managed Volatility PortfolioEquitable Investment Management Group, LLC17,403$0 M0.02%<0.01%+0.1%Jun 30, 2026
🇺🇸 1290 VT Micro Cap PortfolioEquitable Investment Management Group, LLC17,203$0 M0.02%0.03%+30%Jun 30, 2026
🇺🇸 Small Cap Index TrustJohn Hancock Variable Trust Advisers LLC16,769$0 M0.02%<0.01%+20%Jun 30, 2026
🇺🇸 EQ/AB Small Cap Growth PortfolioEquitable Investment Management Group, LLC16,200$0 M0.02%<0.01%+595%Jun 30, 2026
🇺🇸 EQ/Small Company Index PortfolioEquitable Investment Management Group, LLC16,200$0 M0.02%<0.01%+595%Jun 30, 2026
🇺🇸 U.S. Core Equity 1 PortfolioDimensional Fund Advisors LP17,666$0 M0.02%<0.01%newJul 31, 2026
🇺🇸 NVIT Small Cap Index FundNATIONWIDE FUND ADVISORS15,125$0 M0.02%<0.01%no changeJun 30, 2026
🇺🇸 T. Rowe Price Small-Cap Index FundT. Rowe Price Associates, Inc.12,370$0 M0.01%0.01%+51%Jun 30, 2026
🇺🇸 DWS Small Cap Index VIPDWS Investment Management Americas, Inc.12,086$0 M0.01%<0.01%+16%Jun 30, 2026
🇺🇸 EQ/Morgan Stanley Small Cap Growth PortfolioEquitable Investment Management Group, LLC11,592$0 M0.01%<0.01%newJun 30, 2026
🇺🇸 BlackRock Advantage Small Cap Growth FundBlackRock Funds11,550$0 M0.01%<0.01%newJun 30, 2026
🇺🇸 Dimensional US Core Equity Market ETFDimensional Fund Advisors LP13,360$0 M0.02%<0.01%newJul 31, 2026
🇺🇸 JNL/DFA U.S. Small Cap FundJackson National Asset Management, LLC10,768$0 M0.01%<0.01%newJun 30, 2026
🇺🇸 BlackRock Small Cap Index V.I. FundBlackRock Advisors, LLC10,548$0 M0.01%<0.01%+43%Jun 30, 2026
🇺🇸 Voya RussellTM Small Cap Index PortfolioVoya Investments, LLC10,360$0 M0.01%0.01%+26%Jun 30, 2026
🇺🇸 iShares Total U.S. Stock Market Index FundBlackRock Advisors, LLC11,861$0 M0.01%<0.01%newJul 31, 2026
🇺🇸 Fidelity Flex Small Cap Index FundFidelity Management & Research Company LLC11,587$0 M0.01%<0.01%+2.0%Jul 31, 2026
🇺🇸 U.S. Small Cap Equity FundRussell Investment Management, LLC11,500$0 M0.01%<0.01%newJul 31, 2026
🇺🇸 iShares Russell Small/Mid-Cap Index FundBlackRock Advisors, LLC10,548$0 M0.01%<0.01%no changeJul 31, 2026
🇺🇸 SA Small Cap Index PortfolioSunAmerica Asset Management, LLC9,021$0 M0.01%<0.01%+51%Jul 31, 2026
🇺🇸 Victory Extended Market Index FundVictory Capital Management Inc.8,519$0 M0.01%<0.01%+4.7%Jul 31, 2026
🇺🇸 Vanguard Russell 3000 Index FundThe Vanguard Group, Inc.7,403$0 M<0.01%<0.01%+74%May 31, 2026
🇺🇸 PD Small-Cap Growth Index PortfolioPacific Life Fund Advisors LLC6,992$0 M<0.01%0.02%newJun 30, 2026
🇺🇸 Venerable Small Cap Index FundVenerable Investment Advisers, LLC6,168$0 M<0.01%<0.01%+27%Jun 30, 2026
🇺🇸 Nationwide Small Cap Index FundNATIONWIDE FUND ADVISORS7,160$0 M<0.01%<0.01%+41%Jul 31, 2026
🇺🇸 CVT Russell 2000 Small Cap Index PortfolioCalvert Research and Management5,984$0 M<0.01%<0.01%no changeJun 30, 2026
🇺🇸 SmallCap Growth Fund IPrincipal Global Investors, LLC6,645$0 M<0.01%<0.01%+2456%Jul 31, 2026
🇺🇸 Voya VACS Index Series SC PortfolioVoya Investments, LLC5,546$0 M<0.01%0.01%+10%Jun 30, 2026
🇺🇸 VIP Extended Market Index PortfolioFidelity Management & Research Company LLC5,404$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 Vanguard Russell 2000 Growth Index FundThe Vanguard Group, Inc.4,892$0 M<0.01%<0.01%+61%May 31, 2026
🇺🇸 Siit Extended Market Index FundSEI INVESTMENTS MANAGEMENT CORPORATION4,800$0 M<0.01%<0.01%no changeMay 31, 2026
🇺🇸 Dimensional US Core Equity 1 ETFDimensional Fund Advisors LP4,274$0 M<0.01%<0.01%newJul 31, 2026
🇺🇸 ProShares Russell 2000 High Income ETFPROSHARE ADVISORS LLC3,517$0 M<0.01%<0.01%+45%May 31, 2026
🇺🇸 Nationwide Fundamental All Cap Equity PortfolioNATIONWIDE FUND ADVISORS3,882$0 M<0.01%<0.01%newJul 31, 2026
🇺🇸 Strategic Equity Allocation TrustJohn Hancock Variable Trust Advisers LLC3,184$0 M<0.01%<0.01%−33%Jun 30, 2026
🇺🇸 SA U.S. Small Company FundFocus Advisor Solutions, LLC2,900$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 ProShares UltraPro Russell2000PROSHARE ADVISORS LLC2,782$0 M<0.01%<0.01%−20%May 31, 2026
🇺🇸 ProShares Ultra Russell2000PROSHARE ADVISORS LLC2,750$0 M<0.01%<0.01%−21%May 31, 2026
🇺🇸 EQ/Franklin Small Cap Value Managed Volatility PortfolioEquitable Investment Management Group, LLC2,044$0 M<0.01%<0.01%no changeJun 30, 2026
🇺🇸 Destinations Small-Mid Cap Equity FundBrinker Capital Investments, LLC2,075$0 M<0.01%<0.01%no changeMay 31, 2026
🇺🇸 VIP Total Market Index PortfolioFidelity Management & Research Company LLC1,836$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 State Street Total Return V.I.S. FundSSGA Funds Management, Inc.1,831$0 M<0.01%<0.01%no changeJun 30, 2026
🇺🇸 Total Stock Market Index TrustJohn Hancock Variable Trust Advisers LLC1,419$0 M<0.01%<0.01%−12%Jun 30, 2026
🇺🇸 Bridge Builder Small/Mid Cap Growth FundOLIVE STREET INVESTMENT ADVISERS LLC1,307$0 M<0.01%<0.01%no changeJun 30, 2026
🇺🇸 AQR Small Cap Multi-Style FundAQR CAPITAL MANAGEMENT, LLC1,103$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 State Street Balanced Index FundSSGA Funds Management, Inc.359$0 M<0.01%<0.01%no changeJun 30, 2026

Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 91 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.

Insider trading at Eledon Pharmaceuticals, Inc.#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$0
0 purchases, 0 insiders
Sold, 12 months
$0
0 sales, 0 insiders
Net, 12 months
$0
open market only
Insiders on file
31
since
Eledon Pharmaceuticals, Inc.: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed David-Alexandre C. GrosChief Executive Officer, DirectorGrant or award+354,454——363,454Form 4
filed Steven PerrinPresident, DirectorGrant or award+152,353——153,353Form 4
filed David-Alexandre C. GrosChief Executive Officer, DirectorShares withheld for tax-194,791$3.380$658 K168,663Form 4
filed Steven PerrinPresident, DirectorShares withheld for tax-72,138$3.380$244 K81,215Form 4
filed June LeeDirectorOption exercise+3,430——3,430Form 4
filed Jan HillsonDirectorOption exercise+3,430——3,430Form 4
filed John S. McBrideDirectorOption exercise+3,430——3,430Form 4
filed James A. Robinson Jr.DirectorOption exercise+3,430——3,430Form 4

Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals

Markets and events: Eledon Pharmaceuticals, Inc.#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Short interest, 2026-10-30
8.3 M
10.9% of shares · 7.51 days to cover
Shares sold short, last 24 reportsAll stocks →

Stock splits: 1-for-18 reverse split in the period to ; 1-for-9 reverse split in the period to ; 1-for-9 reverse split in the period to ; 1-for-10.53 reverse split

Fails to deliver

  • : 8,641 shares at $3.04
  • : 828 shares at $2.41
  • : 2,000 shares at $2.26
  • : 3,858 shares at $2.13
  • : 3,596 shares at $2.25

Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables

Eledon Pharmaceuticals, Inc. scorecard#

Passes 1 of the 12 checks that could be worked out. Fiscal year 2025; market cap of Oct 30, 2026.

  • Valuation0 of 4
    • ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
    • ✗Price to book below its peers' median3.2×Price to book 3.2× against Biotechnology's median of 2.9×.
    • –Price to sales below its peers' medianNo Price to sales on file.
    • ✗Free cash flow yield above 5%-1.9%Free cash flow is -1.9% of the market value.
    • ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
    • –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
  • Growth0 of 2
    • –Revenue grew in the newest yearRevenue of the year before is not on file.
    • –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
    • –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
    • ✗Earnings per share grew in the newest year-0.52 vs -0.66Diluted EPS -0.52 in fiscal 2025 against -0.66 the year before (report's currency).
    • ✗Net income higher than five years earlier-$46 M-$46 M in fiscal 2025 against -$23 M in 2020.
    • –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
  • Profitability0 of 3
    • ✗Profitable in the newest year-$46 MNet income -$46 M in fiscal 2025.
    • ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
    • –Operating margin above its peers' medianNo operating margin on file.
    • ✗Return on equity above 15%-63.6%-63.6% in fiscal 2025.
    • –Return on invested capital above 10%No return on invested capital on file.
    • –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
  • Financial health1 of 2
    • ✓Short-term assets cover short-term liabilities7.4×Current ratio 7.40 at the end of fiscal 2025.
    • –Debt below equityDebt or equity is not on file (or equity is negative).
    • –Net debt below three years of EBITDANet debt to EBITDA is not on file.
    • –Operating income covers interest five timesInterest expense is not on file.
    • ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
    • –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
  • Shareholder returns0 of 1
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • ✗Share count up no more than 2% in a year68.6%Diluted shares up 68.6% in fiscal 2025.
    • –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
    • –Free cash flow covers dividends and buybacksCash from operations or capital spending is not on file.

Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Eledon Pharmaceuticals, Inc.: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

Eledon Pharmaceuticals, Inc.: statements by fiscal year
PeriodTrendFY 2025to Dec 31, 2025FY 2024to Dec 31, 2024FY 2023to Dec 31, 2023FY 2022to Dec 31, 2022FY 2021to Dec 31, 2021FY 2020to Dec 31, 2020FY 2019to Dec 31, 2019FY 2018to Dec 31, 2018FY 2017to Dec 31, 2017FY 2016to Dec 31, 2016
Income statement
Revenue—————————0
Research and development66523027246.18.16.82.03.2r
General and administrative1719131313106.17.2111.9r
Operating expenses8371438837181614135.1r
Operating income——−43−88−37−18−16−14−13−5.1r
Other non-operating income (expense)4.23.92.70.50.00.10.0−0.00.0−0.5
Income before tax−46−36−117r−88−37−23−16−14−13−5.7
Income tax0.00.400−2.4−0.4———0
Net income attributable to shareholders−46−36−117r−88−35−23−16−14−13−5.7r
Earnings per share, basic-0.52-0.66r-4.73r-6.16-2.33-15.72-24.42r-1.56-2.30-2.46r
Earnings per share, diluted-0.52-0.66r-4.73r-6.16-2.33-15.72-24.42r-1.56-2.30-2.46r
Shares, weighted average (basic)8249251415—————
Shares, weighted average (diluted)82492514151.50.7r9.04.70.4r
Balance sheet
Cash and cash equivalents23214.656851148.813171.1r
Short-term investments111120460——————
Other current assets0.00.1r0.10.00.00.00.10.0r0.00.0r
Current assets13614456608811610.014191.2r
Property, plant and equipment——————0.00.00.00.0r
Right-of-use (leased) assets0.60.90.40.70.80.10.3———
Goodwill——004949—1.91.9—
Total assets16917789931711971117211.2r
Accounts payable3.65.81.02.21.81.40.30.70.40.3r
Current liabilities18123.96.54.42.51.32.5—3.9r
Lease liabilities (non-current)0.30.600.40.4—0.1———
Non-current liabilities—————————0.1
Total liabilities325982r8.66.66.61.52.51.43.9r
Retained earnings−401−356−319r−203−115−80−58−42−28−14r
Shareholders' equity8162r−48r24r1641919.51419−2.7r
Total liabilities and equity16917789931711971117211.2r
Shares outstanding7560241414150.7r9.47.10.4r
Cash-flow statement
Depreciation and amortization—————0.00.00.00.00.0
Share-based compensation10136.58.27.93.21.31.50.60.2r
Cash from operating activities−62−47−40−28−29−15−14−12−15−4.9r
Capital expenditure—————————−0.0r
Cash from investing activities11−70−45——11——230.0r
Shares issued—————9.09.77.54.8—
Cash from financing activities5413433—−0.41109.77.67.92.9r
Change in cash2.316−52−28−29105−4.2−4.316−2.0r
Report10-K10-K10-K/A10-K/A10-K10-K10-K10-K10-K10-K

r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

Executive pay at Eledon Pharmaceuticals, Inc.#

From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.

CEO total pay, fiscal 2025
$3.2 M
Dr. Gros
Other top executives, average
$1.6 M
the CEO earned 2× this
$100 invested is now
$66
Eledon Pharmaceuticals, Inc.: executive pay by fiscal year
Fiscal yearCEO total payActually paidOther executives, average$100 invested
2025Dr. Gros$3.2 M−$315 K$1.6 M$66
2024David-Alexandre C. Gros$5.6 M$6.8 M$3.8 M$181
2023David-Alexandre C. Gros$2.6 M$405 K$1.4 M$79

Source: SEC proxy statement (Form DEF 14A) · as of Dec 31, 2025

Events at Eledon Pharmaceuticals, Inc.#

What the company reported to the SEC within four business days (Form 8-K), newest first.

Warning signs in the last three years

  • Financial statements withdrawnFiling
  • Auditor changedFiling
  • Auditor changedFiling
  • Financial statements withdrawnFiling
  • Auditor changedFiling

Financial statements withdrawn 2 · Auditor changed 3 · Directors and officers 1 · Material agreement 3 · Unregistered share sale 2 · Bylaws or fiscal year changed 2 · Shareholder vote 2 · Results announced 11

Eledon Pharmaceuticals, Inc.: events reported to the SEC
FiledWhat happenedFiling
Results announced8-K
Results announced8-K
Bylaws or fiscal year changedShareholder vote8-K
Results announced8-K
Results announced8-K
Unregistered share sale8-K
Results announced8-K
Material agreement8-K
Results announced8-K
Financial statements withdrawnResults announced8-K
Bylaws or fiscal year changedShareholder vote8-K
Results announced8-K
Auditor changed8-K/A
Auditor changed8-K
Results announced8-K
Directors and officers8-K
Results announced8-K
Material agreement8-K
Unregistered share sale8-K
Material agreement8-K
Financial statements withdrawnResults announced8-K
Auditor changed8-K

Source: SEC EDGAR, Form 8-K item numbers · as of Nov 12, 2026

Acquisitions and funding#

1 acquisitions · 3 private funding rounds before listing

Businesses it acquired

Acquisitions by Eledon Pharmaceuticals, Inc.
AcquiredAcquisition dateCompletionPriceStakeSource
AnelixisSep 2020Sep 2020——Annual report

Private share sales · funding history

Private share sales of Eledon Pharmaceuticals, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
May 2024$50 MPrivate placement after listing$50 to $250 million24equity, optionsSEC
May 2023$35 MPrivate placement after listing$10 to $50 million38equity, optionsSEC
Sep 2020$108 MPrivate placement after listing$50 to $250 million35equitySEC
May 2013$20 MNo. 3$10 to $50 million19equitySEC
Sep 2011$2 MNo. 2Under $2 million6equitySEC
May 2009$10 MNo. 1$10 to $50 million10equitySEC

Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.

Layoffs at Eledon Pharmaceuticals, Inc.#

From US state WARN notices and SEC 8-K restructuring filings, newest first.

People, last 12 months
0
0 notices and filings
People, all years
0
2016–2020
Latest
—
2020-06-11
Eledon Pharmaceuticals, Inc.: people laid off by year and month
YearJanFebMarAprMayJunJulAugSepOctNovDecTotal
2020············—
2016············—
Eledon Pharmaceuticals, Inc.: latest layoffs
AnnouncedPeopleKindWhereSource
Not statedRestructuring planSEC 8-KCompany-wide planFiling
Not statedRestructuring planSEC 8-KCompany-wide planFiling

Source: State WARN notices and SEC 8-K item 2.05

How Eledon Pharmaceuticals, Inc. compares in Biotechnology

  • Market cap$257 M · higher than 48% of 726
  • Price / book3.2× · lower than 47% of 534
  • FCF yield-1.9% · higher than 82% of 449

Peer comparison · Biotechnology

CompanyMarket capP/ENet marginRev. growth
Eledon Pharmaceuticals, Inc.🇺🇸$257 M———
Novo Nordisk A/S🇩🇰$203.2 B13.1×33.1%+10.8%
Vertex Pharmaceuticals Incorporated🇺🇸$134.3 B33.8×30.7%+8.9%
Moderna, Inc.🇺🇸$90.1 B—-110.5%-39.9%
Regeneron Pharmaceuticals, Inc.🇺🇸$84.1 B17.5×28.5%+1.0%
Argenx SE🇳🇱$52.8 B40.9×31.1%+89.9%
CSL Limited🇦🇺$51.6 B—-16.4%—
Samsung Biologics Co., Ltd.🇰🇷$51.5 B40.5×39.2%—
UCB SA🇧🇪$48.6 B26.3×20.1%+31.1%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Oct 30, 2026
Annual results:
For year ending December-2025
Balance sheet:
As of December-2025
Employees:
As of March 13, 2026
Profile updated:
Nov 20, 2026

Figures from Market data, SEC filing, value.today research, SEC annual report, GLEIF register; financial statements from SEC filings.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at Eledon Pharmaceuticals, Inc.? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show Eledon Pharmaceuticals, Inc.'s ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about Eledon Pharmaceuticals, Inc.? Suggest a correction